Genetic variants may help explain who loses more weight and who gets side effects on GLP-1 drugs

Genetic Variants May Help Predict GLP-1 Drug Response and Side Effects, Study Suggests

A major research study conducted using data from over 23 million individuals has identified genetic variants that may help predict how people will respond to popular GLP-1 drugs like semaglutide and tirzepatide, potentially revolutionizing personalized medicine approaches to weight loss and diabetes treatment. The genome-wide association study (GWAS), leveraging the extensive genetic database from 23andMe, discovered that common genetic variants in the GLP1R and GIPR genes play a significant role in determining both weight loss outcomes and the likelihood of experiencing adverse effects on these medications.

GLP-1 receptor agonists have become increasingly popular as treatments for type 2 diabetes and obesity, following multiple high-profile clinical trials demonstrating significant weight loss benefits. However, like all medications, these drugs do not affect all patients equally. While some individuals experience dramatic weight reduction and excellent tolerability, others struggle with side effects or achieve more modest results. The findings from this large-scale genetic study suggest that some of these individual differences may be rooted in genetic variation.

The research identified variations in two key genes as particularly important. The GLP1R gene codes for the GLP-1 receptor itself, the target protein that these medications interact with to produce their effects. The GIPR gene codes for the GIP receptor, which is also involved in the mechanism of action for some of these drugs, particularly tirzepatide, which targets both receptors. The specific genetic variants identified in this study were common across large populations, meaning they could potentially be useful for stratifying patients before treatment begins.

The implications of these findings extend beyond simple curiosity about genetic determinants of drug response. If validated in prospective clinical trials, this knowledge could enable physicians to predict which patients are most likely to benefit significantly from GLP-1 medications and which patients might be predisposed to experience problematic side effects such as nausea and vomiting. This predictive capability would represent a significant advancement in precision medicine, allowing for more informed treatment decisions and better patient selection for these expensive medications.

One of the most pressing challenges in current GLP-1 therapy is the high incidence of gastrointestinal side effects. Many patients experience nausea, vomiting, and other gastrointestinal disturbances that can significantly impact treatment adherence and quality of life. If genetic testing could identify patients at higher risk for severe side effects, clinicians could potentially adjust dosing strategies, recommend preventive medications, or explore alternative treatments proactively.

While these findings are promising, researchers emphasize that further validation is necessary before genetic testing for GLP1R and GIPR variants becomes standard clinical practice. The study identified associations, but clinical implementation will require prospective trials demonstrating that knowing a patient's genetic profile actually improves treatment outcomes. Nevertheless, the research points toward an exciting future where cancer and metabolic disease treatments are increasingly tailored to individual genetic profiles, maximizing efficacy while minimizing adverse effects.